Core Viewpoint - ICU Medical, Inc. is under investigation for potential securities fraud and unlawful business practices following a warning from the FDA regarding its infusion pump products [1][3]. Group 1: FDA Warning and Impact - On April 22, 2025, ICU received a warning letter from the FDA, citing unauthorized changes to two of its infusion pump products, labeling them as "adulterated" and "misbranded" [3]. - The FDA indicated that the modifications could significantly affect the functionality of the devices, particularly concerning the infusion delivery profile and alarm functionality, raising safety and efficacy concerns [3]. - Following the FDA's announcement, ICU's stock price dropped by $6.04 per share, or 4.42%, closing at $130.68 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of ICU investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action [2]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [5].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [2] - Following the FDA announcement, Travere's stock price dropped by $4.35, or 20.57%, closing at $16.80 per share on May 16, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1][2] Group 1: Investigation Details - Pomerantz LLP is representing investors of Fulgent Genetics, Inc. in an investigation regarding claims of securities fraud [1] - The investigation follows a civil investigative demand received by Fulgent from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [2] - Following the disclosure of the civil investigative demand, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share on March 3, 2025 [2] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [3] - The firm has a track record of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - New Fortress Energy Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance in Q1 2025 [1][2]. Financial Performance - New Fortress reported total revenue of $470.5 million for Q1 2025, a decrease from $690.3 million in Q1 2024, representing a decline of approximately 31.8% [2]. - The company experienced a net loss of $197.4 million, or $0.73 per share, compared to a net income of $56.7 million, or $0.26 per share, in the same period of the previous year [2]. Stock Market Reaction - Following the release of the disappointing financial results, New Fortress's stock price fell by $4.27 per share, or 62.98%, closing at $4.27 per share on May 15, 2025 [3].

Core Viewpoint - Krispy Kreme, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in revenue and the suspension of its full-year guidance and dividend payments [1][3]. Financial Performance - On May 8, 2025, Krispy Kreme reported a notable decline in revenue attributed to "consumer softness leading to a decline in doughnut shop transaction volume" [3]. - The company pulled its full-year guidance and suspended future dividend payments due to a challenging environment and efforts to preserve cash [3]. Stock Market Reaction - Following the financial results announcement on May 8, 2025, Krispy Kreme's stock price fell by $1.07 per share, or 24.71%, closing at $3.26 per share [4]. - On May 9, 2025, after analysts from Evercore ISI and Citigroup reduced their price targets for Krispy Kreme, the stock price further declined by $0.53 per share, or 16.26%, closing at $2.73 per share [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Metallus Inc. and its officers or directors, following disappointing financial results that led to a significant drop in the company's stock price [1][3]. Financial Performance - On May 8, 2025, Metallus reported non-GAAP earnings per share of $0.07 for the first quarter of 2025, which was $0.05 below consensus estimates [3]. - The CEO of Metallus indicated that the company experienced volatility in the defense supply chain due to customer manufacturing start-up challenges during the first quarter [3]. - Following the earnings announcement, Metallus's stock price decreased by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025 [3]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Metallus regarding possible securities fraud or other unlawful business practices [1].

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Compass Diversified Holdings (“CODI” or the “Company”) (NYSE: CODI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether CODI and certain of it ...

Core Viewpoint - EchoStar Corporation is under investigation for potential securities fraud and unlawful business practices, following a significant drop in its stock price due to regulatory scrutiny from the FCC regarding its compliance with federal requirements for building a nationwide 5G network [1][3]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of EchoStar investors, focusing on possible securities fraud or other unlawful business practices by the company and its officers [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]. Group 2: Regulatory Scrutiny and Market Reaction - The FCC has initiated an investigation into EchoStar's compliance with federal requirements for its Boost Mobile subsidiary, which aims to establish a competitive wireless operation [3]. - Following the news of the FCC's investigation, EchoStar's stock price fell by $4.01, representing a 16.58% decrease, closing at $20.18 per share on May 12, 2025 [3].

Core Viewpoint - Northrop Grumman Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which included significant charges related to its B-21 bomber program [1][3]. Financial Performance - Northrop Grumman reported revenue of $9.47 billion for Q1 2025, reflecting a 7% year-over-year decline and falling short of consensus estimates by $480 million [3]. - The company incurred a pretax charge of $477 million associated with manufacturing updates for the B-21 bomber program, attributed to inflationary factors by the CEO [3]. - Following the announcement of these results, Northrop Grumman's stock price dropped by $67.25 per share, or 12.66%, closing at $464.08 per share on April 22, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful practices by Northrop Grumman and its officers/directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Wabash National Corporation and its officers or directors [1] Financial Performance - Wabash reported an operating loss of $9.8 million in its Transportation Solutions segment for Q1 2025, a significant decline from an operating profit of $44.25 million in Q1 2024 [3] - The gross profit for Wabash in Q1 2025 was $19 million, down from $76.4 million in Q1 2024 [3] - The company revised its annual revenue forecast to approximately $1.8 billion, a decrease from the previous projection of $1.9 billion made in February 2025 [3] Market Reaction - Following the announcement of its financial results, Wabash's stock price fell by $3.05 per share, or 30.62%, closing at $6.91 per share on April 30, 2025 [4]